Literature DB >> 21940831

Concomitant occurrence of BCR-ABL and JAK2V617F mutation.

Lisa Pieri, Ambra Spolverini, Barbara Scappini, Umberto Occhini, Silvia Birtolo, Alberto Bosi, Francesco Albano, Carmen Fava, Alessandro M Vannucchi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21940831     DOI： 10.1182/blood-2011-07-365007

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

Review 1.  An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms.

Authors:  A Tefferi; J Thiele; A M Vannucchi; T Barbui
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

2.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

3.  Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

Authors:  Mohammad Omar Hussaini; Abu-Sayeef Mirza; Rami Komrokji; Jeffrey Lancet; Eric Padron; Jinming Song
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

4.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 6.  Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Authors:  Yanhua Yue; Wei Wei; Yanting Guo; Fei Wang; Weimin Dong; Yue Liu; Yan Lin; Yang Cao; Weiying Gu
Journal:  Am J Case Rep       Date:  2020-10-06

7.  Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.

Authors:  Friederike Pastore; Stephanie Schneider; Oliver Christ; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Exp Hematol Oncol       Date:  2013-09-05

8.  The concomitant occurrence of JAK2V617F mutation and BCR/ABL transcript with phenotypic expression - an overlapping myeloproliferative disorder or two distinct diseases? - case report.

Authors:  I Ursuleac; Ac Colita; T Adam; C Jardan; A Ilea; D Coriu
Journal:  J Med Life       Date:  2013-03-25

9.  Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.

Authors:  Sarah L McCarron; Karena Maher; Johanna Kelly; Mary F Ryan; Stephen E Langabeer
Journal:  Case Rep Hematol       Date:  2013-09-16

10.  Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.

Authors:  Katia Borgia Barbosa Pagnano; Márcia Torresan Delamain; Mariana Munari Magnus; José Vassallo; Carmino Antonio DE Souza; Daiane DE Almeida; Irene Lorand-Metze
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.